All companies
Visit website
O2 RegenTech
Operating02 REGENTECH LLC
Healthcare · Technology · Founded 2013
Commercializing cost-effective, easy-to-use wound care solutions
Post-money valuation ⓘ
$6.8M
As of Apr 2025 · from 02 RegenTech Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$2,033
Across 1 round since 2023
Latest share price
$6.80
02 RegenTech Common Stock 1 offering price
Financials
FY2021–FY2022 · from SEC filings · hover any figure for its source$0
−$53K
2021
$0
−$18K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021
FY2022
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$53,064
-$18,280
Taxes paid
$0
$0
Balance sheet
Cash
$201
$1,032
Accounts receivable
$0
$0
Total assets
$201
$1,032
Short-term debt
$50,000
$50,000
Long-term debt
$204,500
$223,500
Total liabilities
$254,500
$273,500
Other
Headcount
—
0
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$6.8M
post-money
02 RegenTech Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $2K / $612KPost-money $6.8M
Reg CF annual-report compliance
Not obligated
never closed a Reg CF raise
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 9 filings on EDGARSource: ManualCIK 0001998357Share price $6.80
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.